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ABSTRACT

Grant A. Bledsoe.

Tissue Kallikrein in Cardiac Remodeling and Renal Damage in

Genetic and Salt-Induced Hypertension Rat Models.

(Under the direction of JULIE

CHAO, Ph.D.)
Abnormalities of the tissue kallikrein-kinin system have been identified in the
pathogenesis of hypertension and cardiac and renal diseases. The purpose of this study
was to investigate the effect of exogenous tissue kallikrein gene delivery on heart and
kidney injury in pressure overload and volume overload hypertension using
spontaneously hypertensive rats (SHR) and Dahl salt-sensitive (DSS) rats.
In order to examine the role of kallikrein in cardiac protection, adenovirus
encoding the human tissue kallikrein gene was injected intravenously into SHR.
Expression of recombinant human tissue kallikrein was identified in rat serum by ELISA
and heart and kidney tissue by RT-PCR/Southern blot one week after gene delivery.
Kallikrein gene transfer lowered blood pressure in SHR for the first two weeks, but had
no effect from 3-5 weeks. Five weeks post-injection, SHR receiving kallikrein exhibited
significantly less left ventticular hypertrophy, as denoted by a considerable decrease in
cardiomyocyte size, and collagen accumulation compared to control SHR.

The

protective morphological alterations by kallikrein were associated with decreased levels
of transforming growth factor-J31 (TGF-J31), plasminogen activator inhibitor-! (PAI-l),
and phosphorylated c-jun N -terminal kinase (JNK). In addition, kallikrein gene transfer
promoted neovascularization in the hearts of SHR, which normally have diminished
capillary density. Furthermore, kallikrein's protective effects on cardiac remodeling and

Vlll

capillary density in SHR were accompanied by increased cardiac nitric oxide (NO) and
cGMP production, implicating a role for the NO-cGMP pathway.
The effect of kallikrein gene transfer against salt-induced kidney injury was
investigated in DSS rats. Four weeks after high salt (4% N aCl) loading, when renal
damage was apparent, adenovirus harboring the human tissue kallikrein gene was
injected into DSS rats with or without infusion of the B2 receptor antagonist icatibant.
Kidneys were examined before and two weeks after gene delivery by histochemical and
biochemical analyses. Kallikrein gene delivery attenuated salt-induced renal dysfunction,
as evidenced by a decrease in urinary protein and blood urea nitrogen.

In addition,

kallikrein gene transfer not only attenuated but also reversed inflammatory cell
infiltration,

myofibroblast

accumulation,

hypertrophy induced by high salt intake.

collagen

deposition,

and

glomerular

The morphological changes mediated by

kallikrein were associated with reduced intercellular adhesion molecule-1 (ICAM -1) and
TGF-~1

expression, and cell cycle inhibitory protein (p21, p27) levels.

Moreover,

kallikrein restored NO production and suppressed NADH oxidase activity and superoxide
formation.

Kallikrein's effects were abolished by icatibant, indicating a kinin-B2

receptor-mediated event. These studies provide the novel finding that kallikrein/kinin
acts as an anti-inflammatory agent and an anti-oxidant in attenuating and reversing saltinduced inflammation, fibrosis and glomerular hypertrophy. Collectively, these results
demonstrate that kallikrein/kinin provides beneficial effects against heart and kidney
complications in pressure- and salt-induced hypertension.
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I. GENERAL INTRODUCTION
The Kallikrein-Kinin System
The tissue kallikrein-kinin system (KKS) is comprised of kallikreins, kininogens,
kinins, kininases, and kinin receptors (Bhoola et al. 1992). Tissue kallikrein was first
discovered as a hypotensive substance in human urine (Abelous et al. 1909).

Two

decades later, the substance was identified in the pancreas at much higher levels (Fray et

al. 1928; Kraut et al. 1930), and was given the name kallikrein after the Greek word for
pancreas (kallikreas) due to the initial belief that it originated from that organ. However,
it has since been determined that the majority of urinary kallikrein is secreted by the
distal tubule of the kidney (Beasley et al. 1987). Two types of kallikrein have been
discovered: plasma kallikrein, which is expressed in the liver and secreted into the
circulation, and tissue (or glandular) kallikrein, which is not only present in the blood, but
is also located in various tissues, including heart, kidney, adrenal gland, blood vessels,
salivary gland, and brain (Heber et al. 1978). Besides localization, both kallikreins also
differ in sequence and molecular size.

Furthermore, tissue kallikrein is an acidic

glycoprotein belonging to a family of serine proteases, and has a molecular weight
ranging from 24-45 kDa (Bhoola et al. 1992).
Kinin peptides, which contain the bradykinin (BK) sequence Arg-Pro-Pro-GlyPhe-Ser-Pro-Phe-Arg, are produced from the action of tissue kallikrein on low molecular
weight (LMW) kininogen (Bhoola et al. 1992). Cleavage of LMW kininogen by human
tissue kallikrein releases Lys-BK (also known as kallidin), which can be further
processed by an aminopeptidase enzyme to produce B K. Rat tissue kallikrein, however,
directly produces BK from LMW kininogen.
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Kininase I removes the carboxy Arg

residue from BK or Lys-BK, resulting in the formation of des-Arg9 -BK or des-Arg 10-LysBK, respectively. Kininase II, also known as angiotensin !-converting enzyme (ACE),
degrades kinins to inactive fragments. The use of ACE inhibitors has become a popular
means of not only preventing the generation of the peptide hormone angiotensin II (Ang
II), but also reducing the degradation of kinin levels. Therefore, the beneficial effects of
ACE inhibitors have been partially attributed to the actions of kinins (Linz et al. 1995).
The BK receptors, denoted B 1 and B2, are G-protein-coupled receptors containing seven
transmembrane domains. The kinins BK and Lys-BK bind to the B2 receptor, whereas
des-Arg9 -BK and des-Arg 10-Lys-BK bind to the B1 receptor (Regoli et al. 1990).
Interestingly, the B2 receptor has also been shown to be activated directly by tissue
kallikrein, independent of kinins (Hecquet et al. 2000). The B2 receptor is responsible
for most of the effects mediated by kinin, as this receptor is constitutively expressed in a
wide variety of tissues. On the other hand, the B 1 receptor is normally expressed at low
levels but can be up-regulated by inflammation or stress. Activation of kinin receptors
increases intracellular Ca2+ levels as well as prostaglandin (PGI2 ) and cAMP formation
(Regoli et al. 1990). Free Ca2+ can enhance endothelial nitric oxide synthase (eNOS)
activity and thus NO generation (Venema et al. 1996). NO, in turn, can activate soluble
guanylate cyclase, triggering cGMP production. Through these mechanisms kinin can
elicit a broad range of biological responses, including vasodilatation, blood pressure
reduction, vascular permeability, and endothelial cell proliferation (Regoli et al. 1990).
However, the B2 and B 1 receptor-mediated effects can be blocked by the specific
antagonists icatibant (also known as Hoe140) and des-Arg 9-Leu8-BK, respectively.
Additionally, a specific tissue kallikrein -binding protein, named kallistatin, was
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discovered to inhibit the enzymatic activity of tissue kallikrein (Zhou et al. 1992). An
illustration of the KKS is shown in Scheme 1.

Tissue Kallikrein
KallistatiD

L?v1W Kininogen

Kininase II

---i--·
Kinin

~

Inactive Fragtnent

Des-Ari-kinin

K.lninase I

Bradykinin B 2 Receptor

~ bl?c~·~
(Icatibant)

Bradykinin B1 Receptor
- /
/---

B 1 blocker

NO!! cGl\lP, c~~IP

1

Biological Effects
Scheme 1. Schematic of the tissue KKS indicating the production and regulation of kinin as well as the
molecular response to kinin receptor activation.

Role of the KKS in Hypertension and Cardiovascular Disease
Almost 65 million Americans currently have some form of cardiovascular
disease, such as coronary artery disease, heart failure and atherosclerosis. Hypertension
increases the risk for these cardiovascular events. Numerous studies have established an
association between reduced urinary kallikrein and hypertension in human subjects and
genetically hypertensive rats (Ader et al. 1985; Margolius et al. 1972; Margolius et al.
1974). In addition, researchers have shown that a gene for high urinary kallikrein may be
protective against hypertension (Berry et al. 1989).

Moreover, restriction fragment

length polymorphism analysis has demonstrated that high blood pressure co-segregates
with a kallikrein gene family in spontaneously hypertensive rats (SHR) (Pravenec et al.
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1991).

Along these lines, human tissue kallikrein and kinin B2 receptor gene

polymorphisms in the promoter region are associated with essential hypertension (Gainer
et al. 2000; Song et al. 1997). Since kallikrein production is decreased in hypertension,

the effect of exogenous kallikrein treatment has been examined in several animal models
of hypertension. Injection of adenovirus harboring the human tissue kallikrein gene into
several

hypertensive

animal

models,

including

Dahl

salt-sensitive

(DSS),

deoxycorticosterone acetate (DOCA)-salt, SHR, and 5/6 nephrectomy, was shown to
produce a prolonged reduction in blood pressure for several weeks (Chao et al. 1998b;
Dobrzynski et al. 1999; Jin et al. 1997; Wolf et al. 2000). Futthermore, transgenic rats
and mice over-expressing tissue kallikrein or the kinin B2 receptor display hypotension
compared to controllittermates (Silva et al. 2000; Wang et al. 1997; Wang et al. 1994).
These findings indicate the important regulatory role of the KKS in maintaining blood
pressure homeostasis.
Due to its involvement in blood pressure control, it is not surprising that the KKS
is also considered to be a factor in modulating cardiac function. This is supported by the
detection of kallikrein and kininogen as well as kinin B 2 receptors in cardiac tissue
(Nally et al. 1992; Yayama et al. 2000).

However, mice lacking tissue kallikrein

generate insufficient amounts of kinins and exhibit cardiac developmental and functional
abnormalities (Meneton et al. 2001). In addition, B2 receptor knockout mice develop
hypertension and cardiac fibrosis and hypertrophy (Emanueli et al. 1999; Madeddu et al.
2000). Conversely, transgenic rats over-expressing tissue kallikrein are protected against
isoproterenol-induced cardiac

hypertrophy and fibrosis,

as

determined by the

measurement of heart weight and atrial natriuretic peptide and collagen III expression
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(Silva et al. 2000). Yet when these rats are treated with icatibant, the protective actions
are inhibited, implying a role for the B2 receptor in mediating kallikrein's effects.
Furthermore, improved cardiac function and decreased cardiac hypertrophy and fibrosis
was observed after delivery of the kallikrein gene into hypertensive rats (Chao et al.
1998a; Chao et al. 1998b; Wolf et al. 2000; Yayama et al. 1998). Finally, kallikrein gene
transfer has been shown to protect against cardiac remodeling and improve cardiac
function after acute and chronic myocardial infarction, independent of a blood pressure
response (Agata et al. 2002; Yoshida et al. 2000). This suggests that kallikrein mediates
a cardioprotective effect not solely dependent on its ability to lower blood pressure.
Although local expression of KKS components in the heart has been
demonstrated (Nolly et al. 1992; Yayama et al. 2000), SHR have reduced cardiac
kallikrein and kininogen levels, which may be responsible for the development of left
ventricular hypertrophy in these rats (Sharma et al. 1998). Treatment of stroke-prone
SHR (SHRSP) with ACE inhibitors was shown to enhance cardiac function (Gohlke et al.
1994a; Gohlke et al. 1994b). The beneficial effects of ACE inhibition were abolished by
co-treatment with icatibant, suggesting a role for kinin and the B2 receptor in mediating
some of the protective actions of ACE inhibitors. Evidence has also been provided that
indicates kinins to be partially responsible for the increase in cardiac capillary supply
after ACE inhibitor administration in SHRSP (Gohlke et al. 1997). Furthermore, ACE
inhibition was shown to induce a pro-angiogenic effect via B2 receptor signaling in a
model of hindlimb ischemia (Silvestre et al. 2001).

Collectively, these studies

demonstrate the important role of the KKS in protection against cardiovascular
complications.
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Role of the KKS in Salt-Induced Hypertension and Kidney Disease
Compared to the general population, African-Americans are more susceptible to
salt-induced hypertension (Weinberger 1996).

In fact, three quarters of hypertensive

blacks exhibit an abnormal blood pressure response to salt (Weinberger et al. 1986),
indicating a highly probable genetic contribution to salt sensitivity (Svetkey et al. 1996).
It was recently demonstrated that human tissue kallikrein gene promoter polymorphisms
are associated with hypertension and end-stage renal disease (ESRD) in AfricanAmericans (Yu et al. 2002). It has also been observed that the amount of renal kallikrein
excretion inversely correlates with the severity of renal disease in human patients
(Naicker et al. 1999). In addition, a sodium restriction diet can reduce blood pressure and
increase kallikrein excretion in hypertensive subjects (Margolius et at. 1974; Morgan et
al. 1986).

KKS components have been detected in the kidney. Tissue kallikrein was found
to be localized in the cells of the distal tubule (Scicli et al. 1976; Ward et al. 1977), and
LMW kininogen and B2 receptors co-localized in virtually every structure of the
nephron, most notably the distal tubules and collecting ducts (Song et al. 1996). The
functional role of the KKS in the kidney includes increasing renal blood flow, diuresis
and natriuresis (Bhoola et al. 1992). The importance of salt-induced hypertension on the
renal KKS has been demonstrated by several studies. In DSS rats, high salt intake downregulates renal tissue kallikrein expression and causes a decrease in urinary kallikrein
levels (Bouhnik et al. 1992; Wang et al. 1996). Furthermore, when researchers examined
B2 receptor knockout mice, they found that those fed a high salt diet produce an elevated
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blood pressure response and a reduction in renal blood flow compared to knockout mice
on normal salt (Alfie et al. 1997). Moreover, after unilateral ureteral obstruction, B2
receptor knockout mice develop more pronounced renal fibrosis than wild-type controls
(Schanstra et al. 2002). In contrast, mice over-expressing the B2 receptor have enhanced ·
renal function, accompanied by elevated NO, cAMP, and cGMP levels (Wang et al.
2000). Similarly, adenovirus-mediated delivery of the human kallikrein gene reduced
renal injury, characterized by glomerulosclerosis, protein cast accumulation, tubular
damage, interstitial inflammation, and renal dysfunction in several hypertensive animal
models (Chao et al. 1998a; Chao et al. 1998b; Dobrzynski et al. 1999; Wolf et al. 2000;
Yayama et al. 1998).

Although a reduction in blood pressure accompanied these

protective effects, there is evidence that kallikrein may exert beneficial actions
independent of its ability to lower blood pressure. For example, infusion of the kallikrein
protein significantly decreased kidney damage in the salt-loaded DSS rat without
affecting blood pressure (Hirawa et al. 1999; Uehara et al. 1994).

Additionally,

normotensive rats with gentamycin-induced nephrotoxicity had less kidney damage after
kallikrein gene delivery (Murakami et al. 1998).

Rat Models of Hypertension: The Spontaneously Hypertensive and Dahl SaltSensitive Rat
The SHR is the most commonly used model for studying cardiovascular disease
(Doggrell et al. 1998) as it mimics human essential hypertension. At an early age, the
blood pressure of these rats steadily increases to reach hypertensive levels (Okamoto et
al. 1963), leading to the formation of cardiac hypertrophy and heart failure (Conrad et al.
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1991). As mentioned earlier, SHR have reduced cardiac kallikrein and kininogen levels
(Sharma et al. 1998). SHR also have increased expression of inhibitors to extracellular
matrix (ECM) degrading proteins and decreased collagenase activity (Chen et al. 2000;
Varo et al. 2000) as well as increased mRNA levels of collagen types I and III in the
heart (Ohta et al. 1994). This buildup of ECM proteins leads to cardiac fibrosis.
The salt-sensitive Dahl rat strain was bred almost 50 years ago when it was
observed that severe hypertension developed upon salt intake, in contrast to salt resistant
rats (DSR) (Meneely et al. 1958). Salt-loaded DSS rats develop hypertension and severe
damage in the heart and kidney, and therefore serve as a standard model for examining
the progressive nature of salt-induced cardiac and renal damage (Hirawa et al. 1995;
Sterzel et al. 1988; von Lutterotti et al. 1992).

It is known that oxidative stress,

characterized by superoxide production, contributes to salt-induced hypertension and
nephrosclerosis in the DSS rat (Trolliet et al. 2001). This increase in oxidative stress
may be partly due to low renal superoxide dismutase (SOD) expression, the enzyme that
converts superoxide to hydrogen peroxide (Meng et al. 2002). This was demonstrated by
the administration of the SOD mimetic Tempol, which delayed hypertension and renal
damage (Meng et al. 2003). Addition of the anti-oxidant a-tocopherol (vitamin E) also
prevented renal injury and dysfunction in DSS rats (Atarashi et al. 1997; Forde et al.
2003), further clarifying the role of oxidative stress in kidney damage. Studies have also
shown that NO production is defective in DSS rats on a high salt diet as evidenced by
reduced urinary NO and cGMP excretion (Chen et al. 1993b). However, it was observed
that supplementation with the NO synthase substrate L-arginine attenuated hypertension
and increased NO and cGMP excretion, resulting in renal protection (Chen et al. 1993a;
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Chen et al. 1993b). Collectively, these studies show that the balance of oxidative stress
and NO is central to the effects of high salt on the kidney.
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II. OBJECTIVES
Previous reports have shown that the tissue kallikrein-kinin system plays an
important role in cardiovascular and renal function. Consequently, we hypothesized that
a continuous supply of kallikrein/kinin would provide protection against complications of
the heart and kidney in the setting of hypertension. Therefore, the following studies were
performed in order to examine the effect of human tissue kallikrein gene delivery in
genetically and salt-induced hypertensive rats:

III.

KALLIKREIN GENE DELIVERY ATTENUATES CARDIAC
REMODELING AND PROMOTES NEOV ASCULARIZATION IN
SPONTANEOUSLY HYPERTENSIVE RATS

IV.

KALLIKREIN/KININ PREVENTS AND REVERSES INFLAMMATION,
RENAL FffiROSIS, AND GLOMERULAR HYPERTROPHY IN DAHL
SALT-SENSITIVE RATS
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III. KALLIKREIN GENE DELIVERY ATTENUATES CARDIAC
REMODELING AND PROMOTES NEOVASCULARIZATION IN
SPONTANEOUSLY HYPERTENSIVE RATS
SUMMARY
Hypertension, resulting in left ventricular (LV) hypertrophy and/or fibrosis, can
lead to cardiac dysfunction. Spontaneously hypertensive rats (SHR) develop high blood
pressure and LV hypertrophy at an early age and are a popular model of human essential
hypertension. In order to investigate the role of the tissue kallikrein-kinin system in
cardiac remodeling, adenovirus containing the human tissue kallikrein gene was injected
intravenously into adult SHR and normotensive Wistar Kyoto (WKY) rats. The blood
pressure of WKY rats remained unchanged throughout the experiment. Alternatively,
kallikrein gene transfer reduced blood pressure in SHR for the first 2 weeks, but had no
effect from 3 to 5 weeks.

Five weeks after kallikrein gene delivery, SHR showed

significant reductions in LV/heart weight ratio, LV long axis, and cardiomyocyte size;
however, these parameters were unaffected in WKY rats. Interestingly, cardiac collagen
density was decreased in both SHR and WKY rats receiving the kallikrein gene.
Kallikrein gene transfer also increased cardiac capillary density in SHR, but not in WKY
rats. The morphological changes following kallikrein gene transfer were associated with
decreases in c-Jun N-terminal kinase (JNK) activation as well as transforming growth
factor (TGF)-(31 and plasminogen activator inhibitor (PAI)-1 levels in the heart.

In

addition, kallikrein gene delivery elevated LV nitric oxide (NO) and cGMP levels in both
rat strains. These results indicate that kallikrein-kinin attenuates cardiac hypertrophy and
fibrosis and enhances capillary growth in SHR through the suppression of JNK, TGF-(31,
and PAI-l via the NO-cGMP pathway.
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INTRODUCTION

Hypertension increases the risk of cardiovascular events, such as coronary heart
disease and heart failure. Left ventricular (LV) hypertrophy and/or fibrosis accompanied
with hypertension may contribute to cardiac dysfunction.

Cardiac hypertrophy is

characterized not only by increased myocyte size and protein synthesis, but also
alterations in the expression of cardiac-specific genes (Parker et al. 1991). Numerous
studies have shown that elevated tissue kallikrein levels by gene transfer approach
attenuate hypertension and cardiac hypertrophy in several hypertensive rat models (Chao
et al. 1998b; Jin et al. 1997; Wang et al. 1995; Yayama et al. 1998). In transgenic rats

harboring the human tissue kallikrein gene, isoproterenol-induced cardiac hypertrophy
and fibrosis were reduced compared to control rats, and icatibant (a bradykinin B2
receptor antagonist) abolished this effect (Silva et al. 2000). In addition, bradykinin has
been shown to exert anti-hypertrophic actions on angiotensin (Ang) II-infused isolated rat
hearts via cGMP (Rosenkranz et al. 2002). Furthermore, studies in vitro have shown that
in the presence of endothelial cells, bradykinin can prevent Ang II-induced hypertrophy
in cardiomyocytes by increasing nitric oxide (NO) levels (Ritchie et al. 1998a; Ritchie et
al. 1998b). These studies implicate a role for the kallikrein-kinin system in protection

against hypertrophy.
Hypertrophy is usually, but not always, accompanied by cardiac fibrosis, the
pathological accumulation of extracellular matrix (ECM) components, particularly
collagens I and III and fibronectin. Cardiac fibrosis can develop not only by augmented
collagen

synthesis,

but

also

insufficient
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collagen

degradation

by

matrix

metalloproteinases (MMPs) (Eghbali et al. 1990). Increased interstitial collagen accretion
contributes to abnormal myocardial stiffness, and thus diastolic dysfunction associated
with progressed LV hypertrophy (Weber et al. 1991 ). Cardiac fibrosis and hypertrophy
have been shown to develop in bradykinin B2 receptor knockout mice (Emanueli et al.
1999; Madeddu et al. 2000).

It has also been observed that kinin can reduce the

expression of collagen and fibronectin in cultured cardiac fibroblasts via NO and cGMP
(Kim et al. 1999). These observations provide evidence that kinins have an important
role in the prevention of fibrosis.
Cardiac hypertrophy induced by hypertension is often accompanied by a decline
in capillary supply (Mall et al. 1990). However, angiotensin-converting enzyme (ACE)
inhibitor treatment of spontaneously hypertensive rats (SHR) and stroke-prone SHR was
shown to increase capillary length density, allowing more oxygen and nutrients to reach
hypertrophied cardiomyocytes (Gohlke et al. 1997; Olivetti et al. 1993; Unger et al.
1992). Bradykinin has been implicated to play a role in this effect by ACE inhibitors, as
blockade of the kinin B2 receptor prevented the increase in capillary density during ACE
inhibitor treatment (Gohlke et al. 1997). It has been previously demonstrated in cultured
endothelial cells that stimulation of the bradykinin B 1 and/or B2 receptors results in NO
release and endothelial cell proliferation (D'Orleans-Juste et al. 1989; Morbidelli et al.
1998).

In fact, NO itself has been shown to increase endothelial cell growth by

stimulating cGMP production (Ziche et al. 1993). Hence it seems that kinin can increase
the proliferation of endothelial cells through the generation of NO and cGMP.
Collectively, it appears from these previous studies that kinin induces the proliferation of
endothelial cells and has protective actions against cardiac hypertrophy and fibrosis.
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Based on these in vitro and in vivo observations, we therefore investigated the effect of
kallikrein gene transfer in SHR on cardiac hypertrophy, fibrosis, and neovascularization.
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METHODS

Animal treatments
Eleven-week old male (approximately 250 g) SHR and WKY rats (SpragueDawley Harlan, Indianapolis, IN) were used in this study. The rats were housed at a
constant room temperature with a 12-hr light/dark cycle and had free access to tap water
and rat chow. All procedures complied with the standards for care and use of animal
subjects as stated in the Guide for the Care and Use of Laboratory Animals (Institute of
Laboratory Resources, National Academy of Sciences, Bethesda, MD).

Preparation of replication-deficient adenovirus vector Ad.CMV-TK
Human kallikrein plasmid DNA fragment along with the human cytomegalovirus
(CMV) promoter was inserted at the Xho I and Bgl II site of Kan-pShut plasmid.

Subsequently, the 4F2 enhancer and bovine growth hormone poly(A) sequence was
inserted at the Xho I site of the Kan-pShut vector. The Kan-pShut plasmid was modified
from pBluescript (Stratagene, La Jolla, CA) by insertion of a kanamycin-resistant gene
expression unit.

The expression cassettes of human kallikrein eDNA along with the

kanamycin-resistant gene were released with 1-Ceu I and PI-See I and inserted at the
same sites of pAdHM4 plasmid (kindly provided by Dr. Mark A. Kay, Stanford
University Medical Center), a backbone vector of El!E3-deleted adenovirus.

The

expression cassettes of human kallikrein cON A along with the E 1/E3-deleted adenoviral
backbone DNA was released with Pac I and transfected into 293 cells.
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The El/E3-

deleted adenovirus was generated and amplified through six passages. Purification of
adenovirus Ad.CMV-TK was performed as previously described (Becker et al. 1994).

Intravenous delivery of Ad.CMV-TK and blood collection
Rats were randomly divided into two groups. The Ad.CMV-TK adenovirus was
injected into the tail vein of one group at a dosage of 5 x 10 11 plaque-forming units
(pfu/rat). The other group received no injection and was used for control. For blood
collection, unanesthetized rats were placed in a 37°C incubator for 10-15 min. Rats
were then transferred to a plastic holder and an insulin syringe was used to withdraw
blood from the tail vein. Seven hundred J.ll of blood were withdrawn from all rats in the
kallikrein group and from two rats from the control group at predetermined time points
for the human tissue kallikrein ELISA analysis. After collection, blood samples were
centrifuged at 1,000 x g for 20 min and sera were removed and stored at -20°C.

Human tissue kallikrein RT-PCR/Southern blot and ELISA
One week after kallikrein gene delivery, total RNA from various organs was
collected and RT-PCR/Southern blot analysis for human tissue kallikrein was performed
as previously described (Wang et al. 1995). The levels of immunoreactive human tissue
kallikrein in rat sera were determined by an ELISA specific for human tissue kallikrein
as previously described (Wang et al. 1995).

Blood pressure measurement
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Systolic blood pressure was measured with DASYlab 5.5 software (Kent
Scientific Corporation, Turrington, CT) by the tail-cuff method. Unanesthetized rats
were placed in a plastic holder resting on a warm pad maintained at 37°C during the
measurements. Average readings were taken for each animal after the animals became
acclimated to the environment. Body weight and heart rate were recorded at the time
blood pressure was monitored.

Nitrite/nitrate assay and Western blot analysis
One week after kallikrein gene delivery, a subset of rats was sacrificed. LV
tissue (0.3 g) was homogenized in 1.5 ml of lysis buffer (25 mM Tris-HCl, pH 7 .4, 1%
Triton X-100, 0.1% sodium dodecyl sulfate [SDS], 2 mM ethylenediamine tetraacetic
acid [EDTA]) containing 1:100 protease inhibitor cocktail (Sigma, St. Louis, MO) and
centrifuged at 14,000 rpm at 4°C for 30 min. The supernatants were stored at -80°C.
LV nitrite levels were determined by fluorometric assay (Misko et al. 1993).
Briefly, five J.!l of 40 J.!M nicotinamide adenine dinucleotide phosphate (f3-NADPH,
reduced form, Sigma, St. Louis, MO) and 5 J.!l of 14 mU nitrate reductase (Sigma) were
added to 40 J.!l of LV homogenate and the mixture was allowed to stand for 5 min at
room temperature. Fifty J.!l of ddH20 and 10 J.!l of 2,3-diaminonaphthalene (50 J..Lg/ml in
0.62 N HCI) were then added. After a 20 min incubation, the reaction was stopped by
addition of 2 ml of 0.07 N NaOH in a cuvette.

Fluorescence was measured at an

excitation of 365 nm and emission at 450 nm. Sodium nitrite standard measurements,
with a dilution range from 0.1 J.!M to 10 J.!M in 20 mM Tris-HCl, pH 7 .6, were
performed similarly but in the absence of f3-NADPH and nitrate reductase.
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Left ventricular homogenates were used for Western blot analysis using specific
antibodies for phospho-INK, total JNK (Cell Signaling Technology, Beverly, MA),
PAI-l and TGF-(31 (Santa Cruz Biotechnology, Santa Cruz, CA). Signals were detected
by chemiluminescence (PerkinElmer Life Sciences, Boston, MA). The densities of the
protein bands were determined using NIH Image software. Protein concentrations were
determined by Lowry's method.

Radioimmunoassays of cardiac cGMP and cAMP
One week after kallikrein gene delivery, a subset of rats was sacrificed. Left
ventricles were homogenized in 10 volumes of O.lN HCL

The homogenates were

centrifuged at 15,000 g for 30 min, and aliquots of the supernatants were used for the
assay. Protein concentrations were determined by Lowry's method. Cardiac cGMP and
cAMP levels were determined by radioimmunoassay as previously described (Brooker et
al. 1979; Yoshida et al. 2000).

Cardiac morphological parameters and histological examinations
Rats were sacrificed five weeks after adenovirus injection and hearts were
removed and weighed. The atria were then cut away and the right ventricular free wall
was carefully dissected from the left. The intraventricular septum was included in the LV
weight. Left ventricular enlargement was determined by measuring the distance from the
atrial valve to the apex; this measurement was termed LV long axis. Left ventricles were
then fixed in 4% formaldehyde solution and placed in 70% ethanol for storage. After
fixation, the ventricles were cut into 3 transversal slices (1 basal, 1 mid, and 1 apical,
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2mm thick each), which were dehydrated and embedded. One 4 Jlm thick section was
obtained from each slice.
For measurement of cardiomyocyte size, LV sections were stained by the Gordon
and Sweet silver method for reticulin. At 400x magnification, 100 cardiomyocytes were
chosen randomly per slide and traced using NIH Image software. LV sections underwent
Sirius red staining or collagen I immunohistochemistry for the determination of the extent
of fibrosis.

For each section, 10 fields were analyzed in the LV wall at 200x

magnification. Adobe Photoshop software was used to determine the percent of collagen
staining

to

total

LV

tissue,

which

was

expressed

as

collagen

density.

Immunohistochemistry was performed using the Vectastain Universal Elite ABC Kit
(Vector Laboratories, Burlingame, CA) and following the supplied instructions.

LV

sections were incubated at 4°C overnight with Factor VIII (von Willebrand factor)
antibody (DAKO Corporation, Carpinteria, CA), rat endothelial cell antigen (RECA-1)
antibody (Serotec, Raleigh, NC), or collagen I antibody (Sigma). In order to determine
capillary density, 10 to 20 random fields of LV sections stained with Factor VIII or
RECA-1 antibody were selected at 400x magnification and immunostained capillaries
were counted.

Statistical analysis
Data were analyzed ustng standard statistical methods, ANOVA and unpaired
Student's t-test. Group data are expressed as mean ± SEM. Values of all parameters were
considered significantly different at a value of P<0.05.
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RESULTS

Effect of kallikrein gene delivery on blood pressure in SHR and WKY rats
The effects of adenovirus-mediated kallikrein gene transfer on systolic blood
pressure were monitored in SHR and WKY rats before injection and every week
afterwards (Figure 1). SHR receiving kallikrein gene transfer maintained a significantly
lower blood pressure than the SHR control group for 2 weeks. Before gene delivery,
basal systolic blood pressure for both SHR groups was 180

± 1 mmHg. At week 1, the

blood pressure of SHR receiving kallikrein gene transfer decreased to 170
whereas the blood pressure of the SHR control group rose to 184

± 4 mmHg,

± 2 mmHg (P<0.01).

At week 2, the blood pressure of SHR receiving Ad.CMV-TK was still significantly
lower than the SHR control group (178 ± 4 vs. 187 ± 2 mmHg, P<0.05). However, at
weeks 3 and 4 there was no significant difference between the experimental and control
SHR groups. Systolic blood pressures of control WKY rats and WKY rats receiving
kallikrein gene delivery were also monitored at the same time periods. Throughout the
experiment, the blood pressure of WKY control rats remained stable, ranging from 126 ±

2 to 128 ± 3 mmHg, and WKY rats receiving the kallikrein gene showed no significant
decrease in blood pressure.

Expression of human tissue kallikrein
Total RNA was prepared from various organs and RT-PCR/Southem blot was
performed using oligonucleotides specific for human tissue kallikrein.

As shown in

Figure 2A, human tissue kallikrein mRNA was detected in the heart, kidney, adrenal
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gland, lung, and liver of SHR receiving kallikrein gene delivery, but not in control SHR.
Expression of human tissue kallikrein mRNA was also detected in WKY rats following
gene transfer (data not shown). Immunoreactive human tissue kallikrein levels in rat sera
were measured by an ELISA specific for human tissue kallikrein (Figures 2B & C). Rat
serum was collected at 3 days post-injection and every week for 4 weeks. The peak level
of immunoreactive human tissue kallikrein in the serum was at 3 days post-injection, with
6693.6 ± 1541.9 ng/ml for WKY rats and 7920.2 ± 1728.7 ng/ml for SHR, and levels
declined thereafter. No immunoreactive human tissue kallikrein was detected in the sera
of SHR or WKY control rats.

Effect of kallikrein gene delivery on cardiac NO, cGMP and cAMP levels
A subset of rats from each group was sacrificed one week after gene delivery to
measure cardiac NO, cGMP and cAMP levels (Figure 3). Kallikrein gene delivery in
both SHR and WKY rats significantly increased NO levels over control rats, as
determined by nitrate/nitrite assay.

WKY rats receiving kallikrein gene transfer had

higher LV nitrite levels (129.8 ± 9.3 pmol/mg protein, P<0.05) than control WKY rats
(93.1 ± 7.2 pmol/mg protein). Kallikrein gene delivery in SHR also increased LV nitrite
levels (158.5

± 8.2 pmol/mg protein, P<0.05) compared to control SHR (113.3 ± 13.6

pmol/mg protein). WKY rats receiving kallikrein gene transfer had significantly higher
cGMP levels (0.153

± 0.007 pmol/mg protein, P<0.01) than control WKY rats (0.101 ±

0.008 pmol/mg protein).

Kallikrein gene delivery in SHR also resulted in increased

cGMP levels in the LV over control SHR (0.105 ± 0.006 pmol/mg protein vs. 0.083 ±
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0.005 pmollmg protein, P<0.05).

However, cAMP levels remained unchanged after

kallikrein gene delivery in both WKY rats and SHR.

Effect of kallikrein gene delivery on cardiac hypertrophy
Five weeks after gene delivery, rats were sacrificed and morphological parameters
of the heart were measured (Figure 4).

SHR receiving the kallikrein gene had

significantly decreased LV weight to heart weight ratio (0.76 ± 0.01 g/g, P<0.05)
compared to control SHR (0.80

± 0.01 g/g). The LV long axis, a measure of LV

enlargement, was also significantly reduced in SHR receiving kallikrein gene transfer
(12.4 ± 0.3 mm, P<0.05) compared to control SHR (13.2 ± 0.2 mm). However, these
parameters were not affected in WKY rats receiving the kallikrein gene compared to
WKY control rats. In addition, LV weight to heart weight ratio and LV long axis were
significantly higher in control SHR compared to WKY control rats.

The effect of

kallikrein gene transfer on cardiomyocyte size in SHR and WKY rats was determined by
Gordon and Sweet silver staining of LV sections (Figure SA). Quantitative analysis
showed that WKY rats receiving the kallikrein gene had similar average cardiomyocyte
size (374.0 ± 5.6 J..Lm2 ) as that of control WKY rats (366.9 ± 6.3 J..Lm2 ) (Figure 5B). In
contrast, kallikrein gene delivery in SHR significantly reduced cardiomyocyte size (480.5

± 14.8 J..Lm2 , P<0.01) compared to control SHR (543.1 ± 15.2 J..Lm2). It was also evident
that both SHR groups had significantly larger cardiomyocytes compared to WKY rats
(P<0.01).
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Effect of kallikrein gene delivery on cardiac collagen accumulation
LV sections were stained with Sirius red for determination of collagen density
(Figure 6A). Cardiomyocytes stain yellow and collagen stains red. Morphologically,
kallikrein gene delivery appeared to attenuate collagen density in both SHR and WKY
rats. Quantitative analysis revealed that kallikrein gene delivery significantly reduced
collagen density in both rat strains (Figure 6B). Evaluation of Sirius red stained LV
sections showed that collagen density was reduced from 4.25 ± 1.03% to 2.29 ± 1.18%
(P<0.05) in WKY rats and from 8.58 ± 2.17% to 3.43

+ 0.77% (P<0.0001) in SHR after

kallikrein gene transfer. Interestingly, collagen density in SHR receiving kallikrein gene
delivery was normalized to that of WKY control rats.

In order to further verify the

reduction on collagen density, LV sections were immunostained with collagen I antibody
(Figure 7 A). Consistent with the results from Sirius red staining, it was observed that
kallikrein gene delivery reduced collagen I levels in both SHR and WKY rats. Indeed,
quantitative analysis showed that collagen I density was significantly reduced in both rat
strains receiving the kallikrein gene compared to their controls (Figure 7B). Kallikrein
gene delivery in WKY rats decreased collagen I staining from 4.79 ± 1.25% to 1.97 ±
0.96% (P<0.05). In SHR, kallikrein gene delivery reduced collagen I density from 8.34 ±
1.95% to 3.87 ± 0.62% (P<0.0001). Additionally, SHR control rats had significantly
more collagen I staining the WKY control rats (P<0.01).
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Effect of kallikrein gene delivery on cardiac TGF-J31 and PAI-l levels and JNK
phosphorylation
Since transforming growth factor (TGF)-P 1 is such a powerful regulator of
extracellular matrix production (Wells 2000), we evaluated the effect of kallikrein gene
transfer on cardiac TGF-P 1 protein expression by Western blot. As shown in Figure 8,
kallikrein gene delivery in both SHR and WKY rats reduced TGF-P1 protein levels
compared to control groups. Plasminogen activator inhibitor (P Al)-1, which is induced
by TGF-P1 (Wells 2000), inhibits tissue and urokinase plasminogen activators. In tum,
plasminogen activators convert plasminogen to plasmin, a protease that is known to
mediate matrix degradation and activate matrix metalloproteinases.

We showed that

kallikrein gene transfer decreased cardiac PAI-l levels compared to control groups

(Figure 9).
The mitogen-activated protein kinases (MAPKs) ERK and JNK are known to be
involved in the regulation of cardiac hypertrophy (Molkentin et al. 2001). Therefore, we
investigated the effect of kallikrein gene transfer on MAPK activation by Western blot in
the left ventricles of SHR and WKY rats. The phosphorylation of JNK (p54 and p46)
was decreased in rats receiving the kallikrein gene compared to controls (P<0.05), as
shown in Figure 10. It is interesting that although kallikrein gene delivery had no effect
on cardiomyocyte size in WKY rats, a reduction in phospho-JNK was observed. No
difference was observed for ERKl/2 in both rat strains (data not shown).
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Effect of kallikrein gene delivery on cardiac capillary density
SHR receiving kallikrein gene transfer had significantly more capillaries
immunostained by antibody to Factor VIII (2485 ± 51 cap./mm2 , P<O.Ol) compared to
SHR controls (2163 ± 46 cap./mm2 ) (Figures llA & B).

However, Factor VIII

immunostaining showed that kallikrein gene delivery in WKY rats had no effect on
cardiac capillary density. It was also observed that control SHR had significantly lower
capillary density compared to WKY control rats (2709 ± 118 cap./mm2 , P<0.01). In
order to verify the results from the Factor VIII immunostaining, LV tissue sections were
immunostained with RECA-1 (Figure 12A). Quantification of the RECA-1 staining was
consistent with the Factor VIII staining (Figure 12B).

These results showed that

capillary density in WKY rats was not altered after kallikrein gene delivery. On the other
hand, SHR receiving the kallikrein gene had significantly higher capillary density (2281
± 136 cap./mm2 , P<0.005) compared to the SHR control group (1549 ± 131 cap./mm2).
SHR control rats also had significantly lower capillary density than WKY controls (2257
±58 cap./mm2 , P<O.Ol).
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Figure 1. Systolic blood pressure of SHR and WKY rats before and after intravenous
injection of Ad.CMV-TK. Data are expressed as mean± SEM.
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Figure 2. Expression of human tissue kallikrein after gene delivery. (A) Expression of
human tissue kallikrein mRNA by RT-PCR/Southern blot in SHR after kallikrein gene
delivery. Time-dependent expression of human tissue kallikrein in ra serum after gene
delivery in (B) WKY rats and (C) SHR. Data are expressed as mean± SEM (n=5-8).
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Figure 3. Effect of kallikrein gene delivery on cardiac (A) NOx (n=5-6), (B) cGMP (n=3-

5), and (C) cAMP levels (n=3-7). Data are expressed as mean± SEM.

(A)

* P<0.05 vs. WKY Control

(B)

t P<0.005 vs. SHR Control

200----~------------~

* P<0.0005 vs. WKY Control

t P<0.05 vs. SHR Control
0.2 ,-------------------,
0.16
0.12
0.08
0.04
0

(C)

28

Figure 4. Morphometric analysis of the left ventricle. (A) Left ventricular weight to

heart weight (LVW/HW) ratio. (n=6-11 ). (B) Left ventricular long axis (LVLA) (n=611). Data are expressed as mean± SEM (n=5-8).
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Figure 5. Effect of kallikrein gene delivery on cardiomyocyte size. (A) Gordon and

Sweet silver staining of LV sections; magnification is 400X. (B) Quantification of
cardiomyocyte area, as determined by NIH 1.61 Image software (n=5-11 ). Data are
expressed as mean ± SEM.
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Figure 6. Effect of kallikrein gene delivery on cardiac collagen density determined by
Sirius red. (A) Sirius red staining of LV sections. Sirius red stains collagen fibers red;
magnification is 400X. (B) Quantification of collagen density, expressed as percent
collagen to total cardiac tissue (n=5-ll). Data are expressed as mean± SEM.
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Figure 7. Effect of kallikrein gene delivery on cardiac collagen density determined by

collagen I immunohistochemistry. (A) Collagen I immunostaining of LV sections;
magnification is 400X. (B) Quantification of collagen I, expressed as percent collagen I
to total cardiac tissue (n=2-5). Data are expressed as mean ± SEM.
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Figure 10. Effect of kallikrein gene delivery on JNK phosphorylation in LV tissue.
Representative Western blot (top) and quantitative analysis by densitometry (n=3,
bottom) of phospho- and total JNK. Data are expressed as mean ± SEM.
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Figure 11. Effect of kallikrein gene delivery on cardiac capillary density determined

by Factor VIII immunohistochemistry. (A) Factor VIII immunostaining of LV sections;
magnification is 400X. (B) Quantification of capillary density was determined by counting
individual capillaries in 20 different fields (n=4). Data are expressed as mean± SEM.
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Figure 12. Effect of kallikrein gene delivery on cardiac capillary density determined by RECA-1

immunohistochemistry. (A) RECA-1 immunostaining of LV sections; magnification is 400X.
(B) Quantification of capillary density was determined by counting individual capillaries in 10

different fields (n=2-4). Data are expressed as mean± SEM.
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DISCUSSION

The present study showed that a single intravenous injection of the human tissue
kallikrein gene in an adenoviral vector not only attenuates cardiac hypertrophy and
fibrosis, but also promotes neovascularization in the heart of SHR.

SHR receiving

kallikrein gene delivery showed a rapid and significant decrease in systolic blood
pressure in the first 2 weeks after gene transfer compared to control SHR. At 3 to 5
weeks post-injection, however, no difference was observed in the blood pressures of the
two groups, suggesting that the changes in cardiac morphology may be, in part,
independent of the temporary blood pressure reduction.

This is supported by the

observation that the WKY rats that received the kallikrein gene had a reduction in cardiac
fibrosis despite the inability of kallikrein to significantly lower blood pressure compared
to WKY control rats. Expression of human tissue kallikrein resulted in increased cardiac
NO and cGMP levels in both SHR and WKY rats, but had no effect on cAMP levels.
NO, which stimulates the generation of cGMP (Ziche et al. 1993), would explain the
increase in cardiac cGMP levels in both WKY rats and SHR over their respective
controls after kallikrein gene delivery.

These data suggest that adenovirus-mediated

human tissue kallikrein gene transfer results in cardiac protection via the NO-cGMP
pathway.
Reduced active cardiac kallikrein and kininogen levels have been reported in
SHR, suggesting a possible protective role for the kallikrein-kinin system against
hypertension and LV hypertrophy (Sharma et al. 1998). This protective role of the
kallikrein-kinin system was exemplified in SHR receiving the kallikrein gene, in that LV
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hypertrophy was attenuated in these rats. The regulation of cardiac hypertrophy has been
shown to involve all members of the MAPK family to some extent (Molkentin et al.
2001). However, previous studies in stroke-prone SHR have shown that JNKs, but not
ERKl/2, play an important role in the development of LV hypertrophy (Izumi et al.
1998; Izumi et al. 2000). In these studies, inhibition of angiotensin type 1 (ATl) receptor
and ACE decreased JNK activities, but had no effect on ERK. Consistent with these
findings, our results showed that phosphorylation of JNK (p54 and p46) decreased after
kallikrein gene delivery in both SHR and WKY rat LV tissues, but phosphorylation of
ERKl/2 was unaffected (data not shown).

Cardiomyocyte size and other cardiac

morphological parameters were unaffected in the WKY rats receiving kallikrein gene
transfer yet JNK activation was reduced. Apparently, other factors in addition to reduced
JNK activities affect cardiomyocyte size.
Kallikrein gene transfer attenuated cardiac fibrosis in both SHR and WKY rats as
evidenced by both Sirius red staining and collagen I immunostaining. In addition to
being able to reduce collagen expression (Gallagher et al. 1998; Kim et al. 1999),
bradykinin is a stimulator of plasminogen activator release from endothelial cells (Minai
et al. 2001), which would then initiate the fibrolytic cascade resulting in ECM

degradation. We also observed that

TGF-~1

and PAI-l protein levels were reduced in

the hearts of rats receiving kallikrein gene transfer compared to control groups. This is
significant in that both TGF-~1 and PAI-l are pro-fibrotic factors (Wells 2000).

TGF-~1

is known to stimulate the production of ECM components (e.g., collagens) and their
accumulation by increasing the expression of inhibitors (e.g., PAI-l) that block enzymes
responsible for matrix degradation. Therefore, the combined effects of collagen gene
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down-regulation and collagen protein degradation would result tn reduced cardiac
fibrosis.
We demonstrated that kallikrein gene delivery reduces collagen levels in
association with up-regulation of the NO-cGMP pathway.

This is supported by a

previous study in which kinin prevented collagen expression via NO and cGMP (Kim et
al. 1999). Furthermore, it has been shown that NO can suppress the expression of TGF-

(31 and collagen in cultured mesangial cells (Craven et al. 1997). A potential mechanism
for the anti-fibrotic effect of kallikrein/kinin may involve the decrease in JNK activity,
which would then reduce the activity of the transcription factor activator protein (AP)-1
that regulates TGF-f31, collagen, and PAI-l gene expression (Katai et al. 1992; Keeton et
al. 1991; Kim et al. 1990). The regulation of other factors, either directly or indirectly,

by NO and/or cGMP is also possible.
In the present study, we showed that kallikrein gene deli very in SHR attenuated
hypertension, LV hypertrophy, and cardiac fibrosis, which is in agreement with studies
using ACE inhibitors in SHR and stroke-prone SHR (Gohlke et al. 1997; Olivetti et al.
1993; Unger et al. 1992). In these same studies, an increase in capillary length density
(the three dimensional distribution of capillaries) was also observed, and a role for kinin
was implicated in cardiac angiogenesis after ACE inhibitor treatment (Gohlke et al.
1997).

Although we employed a different method for evaluating capillary growth

(counting the number of capillaries per cardiomyocyte area), our results from both Factor
VIII and RECA-1 immunostaining suggest that kallikrein gene transfer also promotes
neovascularization in the hearts of SHR, leading to enhanced endothelial function. A
recent study by Agata et al. showed that after myocardial infarction, kallikrein gene
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transfer improved cardiac and endothelial function, which was associated with an
increase in NO production (Agata et al. 2002). Moreover, it has been shown that kinin
promotes angiogenesis via production of NO (Parenti et al. 2001). Additionally, several
publications have reported that NO increases endothelial cell proliferation and migration
(Goligorsky et al. 1999; Murohara et al. 1999). Therefore, the elevated levels of cardiac
NO after kallikrein gene transfer appear to be responsible for the observed growth of
capillaries.
In conclusion, kallikrein gene delivery in SHR resulted in attenuation of cardiac
hypertrophy and fibrosis, along with a transient decline in blood pressure. The reduction
in cardiac remodeling was accompanied by increases in NO and cGMP and decreases in
TGF-f31, PAI-l and phospho-JNK levels in the heart. The increase in capillary density
after kallikrein gene delivery was most likely due to augmented NO production, resulting
in neovascularization. Taken together, these findings indicate that the kallikrein-kinin
system plays an important role in cardioprotection.
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IV.
KALLIKREIN/KININ
PREVENTS
AND
REVERSES
INFLAMMATION, RENAL FIBROSIS AND GLOMERULAR
HYPERTROPHY IN DAHL SALT -SENSITIVE RATS
SUMMARY
High salt intake provokes oxidative stress and leads to renal fibrosis in Dahl saltsensitive (DSS) rats. In this study, the effect of kallikrein/kinin in reversing salt-induced
inflammation and renal fibrosis was examined in DSS rats. Four weeks after high salt
(4% NaCl) loading, when renal injury was apparent, adenovirus harboring the human
tissue kallikrein gene was injected into rats with or without infusion of the kinin B2
receptor antagonist icatibant.

Recombinant kallikrein was detected in the urine and

plasma of rats after gene delivery. Kidney function was improved by tissue kallikrein, as
evidenced by diminished urinary protein and blood urea nitrogen levels.

Tissue

kallikrein significantly reduced glomerular sclerosis and tubular protein cast formation
caused by high salt loading.

Kallikrein also restored nitric oxide production and

suppressed NADH oxidase activity and superoxide generation. In addition, kallikrein
reversed salt-induced monocyte/macrophage accumulation in the kidney in conjunction
with decreased intercellular adhesion molecule-1 expression.

Moreover, histological

staining with Sirius red showed that kallikrein gene transfer dramatically reduced
collagen deposition in association with a decline in myofibroblast accumulation and
transforming growth factor-J31 expression.

Furthermore, the reversal of salt-induced

glomerular hypertrophy by kallikrein correlated with the inhibition of cyclin-dependent
kinase inhibitor levels. The protective actions of kallikrein against the progression of
renal injury were abolished by icatibant. These findings indicate that kallikrein prevents
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and reverses salt-induced oxidative stress, inflammation, renal fibrosis, and glomerular
hypertrophy through kinin B2 receptor signaling.
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INTRODUCTION

In the kallikrein-kinin system, the serine protease tissue kallikrein cleaves low
molecular weight kininogen to release the vasoactive peptide kinin (Bhoola et al. 1992).
Binding of kinins to the constitutively expressed B2 receptor results in increased nitric
oxide (NO) and cGMP formation, which elicit various biological responses (Regoli et al.
1990). The B2 receptor can be blocked by the specific B2 receptor antagonist icatibant
(also known as Hoe140).

It has been reported that the amount of renal kallikrein

excretion correlates with the severity of renal disease in human patients (N aicker et al.
1999). African-Americans, who are more susceptible to salt-induced hypertension than
the general population (Weinberger 1996), are also four times more likely to develop
end-stage renal disease (ESRD) than Caucasians. Furthermore, analysis of the human
tissue kallikrein gene promoter has implicated its association with ESRD and
hypertension in African-Americans (Yu et al. 2002). The Dahl salt-sensitive (DSS) rat
has become a standard animal model for studying salt-induced renal damage as it closely
mimics the symptoms seen in human patients sensitive to high salt. Experiments in vivo
have demonstrated that high salt loading in DSS rats results in the down-regulation of
renal kallikrein expression and excretion (Wang et al. 1996). However, intravenous
injection of the human tissue kallikrein gene in these animals improved renal function
and attenuated kidney damage (Chao et al. 1998a; Chao et al. 1998b). In addition, longterm infusion of tissue kallikrein, at a sub-depressor dose, protects against salt-induced
renal injury through a B2 receptor-mediated mechanism (Hirawa et al. 1999; Uehara et
al. 1994). The role of the B2 receptor in protection against kidney injury and renal
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fibrosis has been verified by experiments in B2 receptor knockout mice (Alfie et al.
1997; Schanstra et al. 2002). We have previously shown that kallikrein can reverse saltinduced kidney damage (Chao et al. 1998a) and, more recently, we reported that delivery
of the human tissue kallikrein gene attenuates renal fibrosis in DSS rats by suppressing
oxidative stress and transforming growth factor

(TGF)-~1

expression (Zhang et al. 2004).

Taken together, it is evident that the kallikrein-kinin system plays an important part in
salt-induced renal damage.
Oxidative stress is considered to have a significant role in the development of
renal injury as it can stimulate the expression of pro-inflammatory and pro-fibrotic
factors (Rodriguez-Iturbe et al. 2004). In salt-sensitive hypertension, oxidative stress is
associated with immune cell infiltration (Rodriguez-Iturbe et al. 2004 ). It has also been
demonstrated that enhanced generation of superoxide and reduced nitric oxide (NO)
formation contribute to nephrosclerosis in DSS rats (Chen et al. 1993b; Trolliet et al.
2001). In the damaged kidney, activated macrophages and fibroblasts secrete various
fibrogenic agents, most notably TGF-f3 1, which has been found to be increased after high
salt intake in DSS rats (Tamaki et al. 1996).

TGF-~ 1

is also known to up-regulate the

cyclin-dependent kinase inhibitors p21 and p27 (Shankland et al. 2000; Sharma et al.
1996), which induce the development of glomerular hypertrophy, an important
contributor to glomerulosclerosis. Thus, the ensuing inflammatory process leads to the
accumulation of excessive extracellular matrix (ECM) proteins (Eddy 2000), culminating
in kidney failure.

Considering the importance of inflammation in preceding the

development of fibrosis, we therefore investigated the role of kallikrein/kinin on the
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reversal of renal inflammation, fibrosis, and glomerular hypertrophy in the salt-loaded
DSS rat.
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METHODS

Animal treatments
Four-week-old, male DSS rats (Sprague-Dawley Harlan, Indianapolis, IN) were
housed at a constant room temperature with a 12-hr light/dark cycle and had free access
to tap water and rat chow. All procedures complied with the standards for care and use of
animal subjects as stated in the Guide for the Care and Use of Laboratory Animals
(Institute of Laboratory Resources, National Academy of Sciences, Bethesda, MD). Rats
were fed either a normal salt (0.4% NaCl) or high salt (4% NaCl) diet. Four weeks after
salt loading, those on the high salt diet were injected intravenously via the tail vein with
control empty virus (Ad.Null) or adenovirus carrying the human tissue kallikrein eDNA
under the control of the cytomegalovirus promoter and 4F2 enhancer (Ad.CMV-TK) at a
dose of 4 x 10 10 plaque forming units/rat.

In addition, the bradykinin B2 receptor

antagonist icatibant was delivered by osmotic minipump (0.65 J.Lglhr) along with the
injection of kallikrein adenovirus. Two weeks after gene delivery, the effect of kallikrein
on the kidney was examined by histological and biochemical analyses.

In order to

evaluate the reversal effects of kallikrein/kinin, a group of rats was sacrificed after four
weeks of high salt loading and before viral injection (Pre-injection).

Blood pressure measurement
Systolic blood pressure was measured with DASYlab 5.5 software (Kent
Scientific Corporation, Turrington, CT) by the tail-cuff method. Unanesthetized rats
were placed in a plastic holder resting on a warm pad maintained at 3 7°C during the
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measurements.

Average readings were taken for each animal after the animals had

become acclimated to the environment.

Blood and urine collection
For blood collection, unanesthetized rats were placed in a 37°C incubator for 1015 min. Rats were then transferred to a plastic holder and blood was withdrawn from
the tail vein. Blood was collected 3, 7, and 14 days after virus injection. Twenty-fourhour urine was collected from rats in metabolic cages 1 week after virus delivery. In
order to eliminate contamination of urine samples, animals received only water during
the 24-hour collection period.

Urine was collected and centrifuged at 1,000 x g to

remove particles. Blood and urine were stored at -20°C until analysis.

Assays for blood urea nitrogen, urinary protein and nitrate/nitrite levels
Blood urea nitrogen (BUN) levels were determined using a modified ureaseindophenol method (Zhang et al. 2004 ). Total urinary protein levels were measured
using Bio-Rad DC Protein Assay kit (Bio-Rad Laboratories, Hercules, CA).
Nitrate/nitrite (NOx) levels in urine samples collected 6 days after gene delivery were
measured by a fluorometric assay (Misko et al. 1993 ).

Tissue homogenization and Western blot analyses
Renal tissues were homogenized in lysis buffer (10 mM Tris, pH 7.4, 100 mM
sodium chloride [NaCl], 1 mM ethylenediamine tetraacetic acid [EDTA], 20 mM
sodium pyrophosphate [NaJ>20 7 ], 2 mM sodium orthovanadate [Na3V04 ], 1% Triton
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X-100) containing 1:100 protease inhibitor cocktail (Sigma, St. Louis, MO) and
centrifuged at 15,000 x g at 4°C for 30 min.

After centrifugation, the supernatant

(containing the cytosolic fraction) was removed. In order to extract the nuclear proteins,
pellets were re-suspended in equal volume of lysis buffer and N aCl was added to a final
concentration of 0.6 M. After incubation on ice for 1 hr, the lysates were centrifuged
and the supernatant, containing the nuclear proteins, was removed. Protein levels were
measured using Bio-Rad DC Protein Assay kit (Bio-Rad Laboratories). Western blot
analysis was performed with the use of specific antibodies for intercellular adhesion
molecule (ICAM)-1, p21 Cipl (Santa Cruz Biotechnology, Santa Cruz, CA) and p27Kipl
(BD Transduction Laboratories, San Diego, CA) at a dilution of 1: 1000. Signals were
detected by chemiluminescence (PerkinElmer Life Sciences, Boston, MA).

The

densities of the protein bands were determined using NIH Image software.

Human tissue kallikrein and TGF -Jll ELISA
Immunoreactive human tissue kallikrein levels in rat sera and unne were
determined by ELISA as previously described (Chao et al. 1998a). Total renal

TGF-~ 1

levels were determined by ELISA according to the manufacture's instructions (R&D
Systems, Minneapolis, MN).

Morphological and histological examinations
At the time of sacrifice, kidneys were removed, fixed in 4% formaldehyde
solution and placed in 70% ethanol for storage.
dehydrated and embedded.

After fixation, the kidneys were

Four J..Lm thick sections were obtained from each slice.
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Sections were stained with periodic acid-Schiff (PAS) for morphometric analysis and
with Sirius Red to determine the extent of fibrosis. Sirius red stains collagen fibers red
and cytoplasm gray or yellow. The glomerular area of approximately 20-25 glomeruli
per

kidney

section

was

measured

ustng

Adobe

Photoshop

software.

Immunohistochemistry was performed using the Vectastain Universal Elite ABC Kit
(Vector Laboratories, Burlingame, CA), following the supplied instructions.
sections

were

incubated

at

4 °C

overnight

with

antibodies

Kidney

against

the

monocyte/macrophage marker ED-1 (1:100) (Chemicon, Temecula, CA), a-smooth
muscle actin (a-SMA) (1:100) (Dako Corporation, Carpinteria, CA), transforming
growth factor

(TGF)-~ 1

(1: 100) (Santa Cruz Biotechnology), or proliferating cell nuclear

antigen (PCNA) (1:3000) (Sigma).

Quantification of monocytes/macrophages was

determined by counting ED-1-positive cells in 10 fields at 400x magnification.

Measurement of NADH oxidase activity and superoxide formation
NADH oxidase activity in the renal extracts was measured in the presence of
NADH substrate (100 J..LM) and lucigenin (75 J..LM) by chemiluminescence assay
(Griendling et al. 1994). Light emission levels were expressed as relative light units
(rlu) per minute per mg of protein.

Superoxide production was measured using a

ferricytochrome c reduction assay according to a modified previous protocol
(Griendling et al. 1994). Superoxide levels were quantified by a spectrophotometric
assay based on rapid reduction of ferricytochrome c to

ferrocyto~hrome

c.

Non-

superoxide-dependent reduction of cytochrome c was corrected for by deducting the
activity not inhibited by superoxide dismutase.
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ICAM-1 and TGF-(31 reverse transcription-polymerase chain reaction (RT ..PCR)
Total RNA was extracted from kidney using Trizol reagent (Invitrogen,
Carlsbad, CA). eDNA was transcribed from 1 J..Lg of RNA using a Qiagen Omniscript
RT kit (Qiagen, Valencia, CA). The reaction mixture contained RT buffer, 10 pmols of
dNTP, 10 pmols of random hexamer, and 2 units of Omniscript reverse transcriptase,
and was incubated at 37°C for 1 hr. The primer sequences are as follows: 5' primer (5'TTCCTTCTCTATTACCCC) and 3' primer (3'-GTGAGCGTCCATATTTAG) for
ICAM-1, and 5' primer (5'-CAAAGACATCACACACAGTA) and 3' primer (5'GGTGTTGAGCCCTTTCCAGG) for TGF-J31.

PCR buffer, 10 pmols of primers, and

0.5 units of Taq DNA polymerase were added to the RT mixture, followed by 30 cycles
of PCR (94°C, 1 min; 56°C [ICAM-1] or 50°C [TGF-J31], 1 min; 72°C, 1 min). PCR
products were loaded on 1% agarose gel and subjected to electrophoresis.

Statistical analysis
Data were analyzed using standard statistical methods, ANOV A and unpaired
Student's t-test. Group data were expressed as mean± SEM. Values of all parameters
were considered significantly different at a value of P<0.05.
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RESULTS

Expression of human tissue kallikrein in DSS rats after gene transfer
Immunoreactive human tissue kallikrein levels were measured using a specific
ELISA. Human tissue kallikrein was detected in the urine one week after gene delivery
(15.6

± 3.2 J..Lg/100 g BW/day, n=12) as well as rat sera at 3 days (946.5 ± 163.2 ng/ml,

n=12) and 7 days (107.7 ± 11.4 ng/ml, n=12) after Ad.CMV-TK injection. Human tissue
kallikrein was not detected in sera or urine of rats receiving control Ad.Null virus.

Effect of kallikrein gene delivery on blood pressure
The effects of high salt intake and kallikrein on systolic blood pressure were
monitored in DSS rats before and after gene delivery (Table). DSS rats on a high salt
diet had a significantly higher blood pressure than those on normal salt at 1 week (134.8

± 3.1 vs. 113.7 ± 2.3 mmHg, n=7, P<0.001) and 4 weeks (171.3 ± 5.8 vs. 118.7 ± 2.1
mmHg, n=6-7, P<0.001) after salt loading. At 5 weeks after salt loading (1 week after
gene delivery), kallikrein gene transfer significantly reduced blood pressure compared to

± 3.6 mmHg, n=3-4,

P<0.05).

However, icatibant blocked kallikrein's blood pressure-lowering effect (183.8

± 4.8 vs.

DSS rats receiving Ad.Null (161.4 ± 11.5 vs. 190.4

161.4 ± 11.5 mmHg, n=4, P<0.05). Systolic blood pressure was still significantly higher
in the kallikrein group compared to rats on the normal salt diet (161.4
2.0 mmHg, n=3-4, P<0.001).

± 11.5 vs. 117.2 ±

DSS rats on a normal salt diet were normotensive

throughout the experimental period.
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Effect of tissue kallikrein on urinary protein and BUN levels
Renal dysfunction was determined indirectly by measuring urinary protein and
BUN levels.

Figure 13A shows that high salt loading resulted in higher urinary

excretion of protein 1 week after gene delivery in the Ad.Null group compared to DSS
rats receiving the kallikrein gene (112.5

± 14.3 vs. 65.2 ± 7.0 mg/day/100 g BW, n=5,

P<0.05) and rats fed normal salt (112.5 ± 14.3 vs. 48.6 ± 4.6 mg/day/100 g BW, n=5-6,
P<0.005).

Although icatibant did not significantly reverse kallikrein's effect on

proteinuria, the tendency was evident (79.2 ± 18.8 vs. 65.2 ± 7.0 mg/day/100 g BW, n=56, P=0.45). Kallikrein gene transfer significantly decreased the salt-induced elevation of
BUN in the Ad.Null group at 2 weeks after gene delivery (0.51 ± 0.10 vs. 1.24 ± 0.16
mg/ml, n=3-4, P<0.01), whereas icatibant blocked the effect of kallikrein (1.10 ± 0.29 vs.
0.51 ± 0.10 mg/ml, n=3, P<0.05) (Figure 13B).

Kallikrein/kinin reverses salt-induced renal damage
Renal injury was investigated by PAS staining 4 and 6 weeks after high salt
loading (Figures 14 & 15). Kidneys of DSS rats on a normal salt diet had a healthy
appearance. However, DSS rats on a high salt diet for 4 weeks (Pre-injection) and 6
weeks (Ad.Null) exhibited tubular dilatation and necrosis as well as protein cast
accumulation in the cortex and medulla. In contrast, DSS rats injected with the kallikrein
gene appeared to have less tubular damage and fewer protein casts compared to rats
sacrificed before and after gene delivery.

In addition, DSS rats receiving both the

kallikrein gene and B2 receptor antagonist infusion had similar kidney morphology as the
Ad.Null group.
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Effect of kallikrein gene transfer on urinary NO levels and oxidative stress
As shown in Figure 16A, high salt loading in DSS rats significantly reduced
urinary nitrate/nitrite (NOx) levels 6 days post gene delivery compared to rats on a
normal salt diet (0.93 ± 0.02 vs. 1.57

± 0.14 J..Lmol/day/100 g BW, n=4 or 6, P<0.001).

However, kallikrein gene transfer restored NOx levels to those in the normal salt group
(1.52 ± 0.13 vs. 1.57

± 0.14 J..Lmol/day/100 g BW, n=6). lcatibant infusion, in conjunction

with Ad.CMV-TK delivery, tended to lower NOx production, but not to significant levels
(1.27

± 0.15 vs. 1.52 ± 0.13 J..Lmol/day/100 g BW, n=4-6, P=0.13).
In order to determine the effect of high salt on oxidative stress in the kidney,

NADH oxidase activity and superoxide levels were measured in renal extracts. As shown
in Figure 16B, DSS rats on a high salt diet had significantly higher NADH oxidase
activity than both normal salt rats (7.6 ± 1.6 vs. 3.2 ± 0.4 rlu/min/mg protein, n=3-4,
P<0.05) and those injected with the kallikrein gene (7 .6

± 1.6 vs. 4.4 ± 0. 7 rlu/min/mg

protein, n=6, P<0.05). However, icatibant inhibited kallikrein's ability to decrease saltinduced NADH oxidase activity (7 .9

± 1.0 vs. 4.4 ± 0. 7 rlu/min/mg protein, n=4,

P<0.05). No change in NADPH oxidase activity was observed. Superoxide formation
paralleled NADH oxidase activity (Figure 16C). Superoxide levels were elevated in the
Ad.Null group above those in the normal salt group (6.8 ± 1.2 vs. 3.2 ± 0.8 nmol/min/mg
protein, n=4, P<0.05).

Although kallikrein gene transfer significantly lowered salt-

induced superoxide formation, its effects were diminished by the presence of icatibant
(2.8 ± 1.0 vs. 8.4 ± 1.0 rlu/min/mg protein, n=5-6, P<0.001). These results indicate that
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kallikrein increases NO formation via the kinin B2 receptor, leading to the suppression of
salt-induced oxidative stress.

Kallikrein gene delivery inhibits salt-induced inflammatory cell inf'IItration and
ICAM-1 expression
The effect of high salt on inflammation in the kidney was analyzed by
immunohistochemistry using an antibody against ED-I, a specific marker of monocytes
and macrophages (Figures 17 & 18). In the DSS rats fed a normal salt diet, only a small
number of these mononuclear cells were present.

However, DSS rats with high salt

intake for 4 weeks (Pre-injection group) had a significant accumulation of ED-t-positive
cells, which was more pronounced after 6 weeks of high salt loading (Ad.Null group).
The monocytes/macrophages were primarily localized in the interstitium, though some
staining was also found within glomeruli. Delivery of the kallikrein gene both attenuated
and reversed salt-induced inflammatory cell accumulation in the interstitium and
glomeruli, whereas icatibant blocked kallikrein's effects.

ED-t-positive cells were

counted for quantification of monocyte/macrophage number (Figure 19). Four weeks of
high salt loading resulted in a dramatic accumulation of ED-t-positive cells in the kidney
compared to DSS rats on a normal salt diet (950.4 ± 107.4 vs. 100.8 ± 9.0 cells/mm2 ,
n=4, P<O.OO 1). Kallikrein significantly reduced monocyte/macrophage accumulation in
the kidney compared to DSS rats on a high salt diet for 6 weeks (Ad.Null) (415.4 ± 45.5
vs. 889.3 ± 38.1 cells/mm2 , n=5, P<O.OOl), although the B2 receptor antagonist abolished
kallikrein's effects (957.6

± 49.8 vs. 415.4 ± 45.5 cells/mm2 , n=4, P<O.OOI) to levels

similar to those in the high salt gr~ups.
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Since ICAM-1 is involved in the recruitment of leukocytes to areas of
inflammation, RT-PCR and Western blot analyses were performed in order to examine its
expression in renal extracts. High salt up-regulated ICAM-1 mRNA and protein levels
compared to DSS rats on a normal salt diet (Figure 20). Kallikrein gene transfer lowered
ICAM -1 levels, and this effect was reversed by icatibant administration.

Kallikrein gene transfer inhibits salt-induced renal fibrosis and TGF -~1 expression
In order to determine the role of kallikrein/kinin on renal fibrosis, kidney sections
were stained with Sirius red (Figure 21). DSS rats fed a normal salt diet exhibited a
small amount of interstitial collagen. On the other hand, high salt loading for 4 weeks
increased the accumulation of ECM collagen in the interstitium as well as in glomeruli,
and even more so in the Ad.Null group. Delivery of the kallikrein gene attenuated and
reversed collagen deposition, whereas icatibant blocked this effect. Expression of TGFf31, a pro-fibrotic molecule, was determined by immunohistochemistry of kidney sections

(Figure 22). High salt up-regulated TGF-f31 protein expression as compared to DSS rats
on a normal salt diet, which had virtually no staining.

Localization of TGF-f31 was

primarily in the tubules. Kallikrein gene transfer down-regulated TGF-f31 expression,
whereas administration of the B2 receptor antagonist together with Ad.CMV-TK
injection blocked this effect. RT-PCR and ELISA for TGF-f31 expression verified this
observation (Figure 23).

Figure 23A shows the representative RT-PCR analysis of

TGF-f31 mRNA expression. Compared to the levels in the normal salt group, total renal

•
TGF-f31 protein levels were appreciably elevated after 4 (321.4
pg/mg protein, n=4, P<0.005) and 6 weeks (427.8
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± 32.4 vs. 83.3 ± 7.1

± 94.8 vs. 83.3 ± 7.1 pg/mg protein,

n=4, P<0.001) of high salt loading (Figure 23B). However, TGF-(31 production was
diminished in DSS rats injected with Ad.CMV-TK, significantly below that of the
Ad.Null group (216.5

± 32.7 vs. 427.8 ± 94.8 pg/mg protein, n=4-6, P<0.005).

Administration of icatibant along with Ad. CMV-TK injection abolished the effect of
kallikrein gene delivery alone (360.3 ± 17.6 vs. 216.5 ± 32.7 pg/mg protein, n=4-6,
P<0.05).

Kallikrein

gene

delivery

inhibits

salt-induced

cellular

proliferation

and

myofibroblast accumulation
Myofibroblasts, which contain the features of smooth muscle cells and fibroblasts,
are known to exhibit up-regulated expression of ECM proteins, particularly collagen.
Therefore, immunohistochemistry was performed for a-SMA, a marker of the smooth
muscle phenotype (Figure 24). As expected, blood vessels stained positive for a-SMA.
DSS rats on a high salt diet for 4 and 6 weeks had an increase in a-SMA staining in the
interstitium and glomerular parietal epithelial cells compared to rats fed normal salt.
Although kallikrein gene transfer decreased the accumulation of myofibroblasts induced
by high salt, the B2 receptor antagonist abolished kallikrein's actions.

Cellular

proliferation was detected by immunostaining against PCNA in kidney sections (Figure

25). Very little staining was observed in the normal salt group, whereas the numbers of
proliferating cells were elevated in rats receiving a high salt diet for 4 weeks and were
augmented further in the Ad.Null group. Proliferating cells were localized both in the
tubules and in the interstitium. Kallikrein gene delivery completely reversed the effects
of high salt on renal cell proliferation, as few PCNA-positive cells were observed in this
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group.

Icatibant infusion, however, blocked kallikrein's actions and resulted tn a

considerable amount of proliferating cells.

Kallikrein gene delivery inhibits salt-induced glomerular hypertrophy
Glomerular hypertrophy was determined by measuring the areas of glomeruli in
each group (Figure 26). Glomeruli of DSS rats receiving a high salt diet for 4 weeks
were notably larger than those in the normal salt group (10,590.8 ± 269.1 vs. 8,695.8 ±
251.3 J.tm2 , n=3, P<0.005). Six weeks of a high salt diet provoked a further increase in
glomerular size, significantly over that of the Pre-injection group (11,497.6

± 245.7 J.tm2 ,

n=4, P<0.001). Kallikrein gene transfer, however, completely reversed the salt-induced
glomerular hypertrophy observed in the Pre-injection group (8,705.2 ± 298.8 vs. 10,590.8

± 269.1 J.tm2 , n=3-4, P<0.001), and icatibant administration blocked kallikrein's actions
(10,500.9 ± 210.7 vs. 8,705.2 ± 298.8 Jlm2 , n=4, P<0.001). The glomerular hypertrophy
data corresponded to the levels of cyclin-dependent kinase inhibitors p21 and p27, as
demonstrated by Western blot analysis (Figure 27). DSS rats on a high salt diet injected
with Ad.Null had

el~vated

protein levels of both p21 and p27 in renal nuclear extracts

compared to rats on normal salt. Kallikrein gene delivery completely abolished p21 and
p27 levels, whereas antagonism of the B2 receptor restored levels comparable to those in
the Ad.Null group.
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Table. Systolic blood pressure of DSS rats before and after gene delivery.

Normal Salt

High Salt

Ad.Null

*

134.8 ± 3.1

NA

NA

Ad.CMV-TK
+ Icatibant
NA

± 2.1 *

171.3 ± 5.8

NA

NA

NA

NA

190.4 ± 3.6

1 week

113.7 ± 2.3

4 weeks

118.7

5 weeks

117.2 ± 2.0

t

Ad.CMV-TK

161.4 ± 11.5

t

183.8 ± 4.8

Blood pressure values are expressed in units of mmHg. NA =not applicable.

* P<0.001

vs. High Salt. t P<0.05 vs. Ad.Null and lcatibant. Data are expressed as means ± SEM.
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Figure 13. Effect of kallikrein/kinin on urinary protein and BUN levels. (A) Total urinary

protein levels were measured in urine collected 1 week after gene transfer. (B) BUN levels
were measured 2 weeks after gene transfer. Data are expressed as mean± SEM.
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Figure 14. Kallikrein/kinin reversed salt-induced kidney injury, as determined by
histological staining of renal cortex with PAS. Magnification is 200x.

Normal Salt (0.4% NaCI)

Pre-injection
(4% NaCI, 4 weeks)

Ad.Null
(4% NaCI, 6 weeks)

Ad.CMV-TK + Icatibant
(4% NaCI, 6 weeks)

Ad.CMV-TK
(4% NaCI, 6 weeks)
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Figure 15. Kallikrein/kinin reversed salt-induced kidney injury, as determined by
histological staining of renal medulla with PAS. Magnification is 1OOx.

Normal Salt (0.4% NaCI)
~

:.

Pre-injection
(4% NaCI, 4 weeks)

Ad.Null
(4% NaCI, 6 weeks)

' ....... ....,.•.,.l ~·'

Ad.CMV-TK + Icatibant
(4% NaCI, 6 weeks)

Ad.CMV-TK
(4% NaCI, 6 weeks)
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Figure 16. Effect of kallikrein/kinin on (A) urinary nitrate/nitrite (NOx) levels 1 week
after gene delivery, and renal (B) NADH oxidase activity and (C) superoxide formation 2
weeks after gene transfer. Data are expressed as mean± SEM.
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Figure 17. Kallikrein/kinin reversed salt-induced inflammatory cell infiltration, as
determined by immunohistochemical staining for ED-1, a specific marker for monocytes
and macrophages in the cortex. Magnification is 200x.

Normal Salt (0.4% NaCl)

Pre-injection
(4% NaCl, 4 weeks)

Ad.Null
(4% NaCl, 6 weeks)

Ad.CMV-TK + Icatibant
(4% NaCl, 6 weeks)

Ad.CMV-TK
(4% NaCl, 6 weeks)

64

Figure 18. Kallikrein/kinin reversed salt-induced inflammatory cell infiltration, as
determined by immunohistochemical staining for ED-1, a specific marker for monocytes
and macrophages in the medulla. Magnification is 200x.
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Figure 19. Quantification of ED-1-positive cells in the cortex and medulla. Data are

expressed as mean ± SEM.

* P<0.001 vs. other groups
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Figure 20. Representative RT-PCR and Western blot analysis (top) for the
determination of renal mRNA and protein expression of the leukocyte adhesion
molecule ICAM -1.

~-actin

was used for loading control. Densitometry was performed

for quantitative analysis of ICAM-1 protein levels (bottom).

Data are expressed as

mean± SEM.
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Figure 21. Kallikrein/kinin reversed salt-induced renal fibrosis, as determined by Sirius
red staining of kidney cortex. Sirius red stains collagen fibers red and cytoplasm yellow.
Magnification is 200x.

